Filing Details

Accession Number:
0001567619-21-012030
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-11 17:39:43
Reporting Period:
2021-06-11
Accepted Time:
2021-06-11 17:39:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1724344 Entasis Therapeutics Holdings Inc. ETTX Pharmaceutical Preparations (2834) DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1080014 Innoviva, Inc. 1350 Old Bayshore Highway Suite 400
Burlingame CA 94010
No No Yes No
1842875 Innoviva Strategic Opportunities Llc 1350 Old Bayshore Highway Suite 400
Burlingame CA 94010
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-06-11 6,268,975 $2.00 10,000,000 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrants to Purchase Common Stock Acquisiton 2021-06-11 6,268,975 $2.00 6,268,975 $2.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,000,000 2021-06-11 2026-06-11 No 4 P Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 18,672,897 Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Warrants to Purchase Common Stock $0.00 18,672,897 18,672,897 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
18,672,897 18,672,897 Direct
Footnotes
  1. As reflected in the Amendment No. 5 to Schedule 13D filed by Innoviva, Inc. ("INVA") and Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of INVA ("ISO" and together with INVA, the "Reporting Persons") with the U.S. Securities and Exchange Commission on June 11, 2021 (the "Schedule 13D/A"), in connection the closing that occurred on June 11, 2021 pursuant to a securities purchase agreement, dated as of May 3, 2021 (the "Purchase Agreement" and, such closing, the "Closing"), by and between Entasis Therapeutics Holdings Inc. (the "Issuer") and ISO, ISO acquired 6,268,975 shares of common stock of the Issuer ("Shares") and warrants to purchase an additional 6,268,975 Shares ("Warrants" and together with the Shares, the "Security") for an aggregate price of $2.00 per Security as set forth in this Form 4. ISO previously acquired 3,731,025 shares of common stock of the issuer and warrants to purchase an aggregate 3,731,025 shares of common stock of the Issuer on May 3, 2021.
  2. (2) INVA acquired an aggregate of 18,672,897 shares of common stock of the issuer and warrants to purchase an aggregate 18,672,897 shares of common stock of the Issuer in transactions on April 22, 2020, June 11, 2020 and September 1, 2020.